IceCure Medical Secures $4 Million Financing with 16M Warrants
IceCure Medical entered securities purchase agreements to sell 8 million ordinary shares at $0.50 each, raising approximately $4.0 million in a registered direct offering. Concurrently, it issued Series B and C warrants for 8 million shares at a $0.55 exercise price, exercisable immediately with expiries of five and one year.
1. Offering Details
IceCure Medical entered into securities purchase agreements with healthcare-focused institutional investors to sell 8 million ordinary shares at $0.50 per share, generating gross proceeds of approximately $4.0 million. The shares were offered through an effective shelf registration statement declared effective on March 24, 2026.
2. Warrant Issuance Terms
In parallel, the company issued unregistered Series B warrants to purchase 8 million shares expiring five years from issuance, and Series C warrants for another 8 million shares expiring one year post-issuance. Both warrant series carry an exercise price of $0.55 per share and are exercisable immediately upon issuance.
3. Use of Proceeds and Closing
The offering is expected to close around March 27, 2026, subject to customary conditions. Net proceeds will be directed toward working capital needs and general corporate purposes, bolstering liquidity for ongoing operations.